Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Jim Lamb who wrote (7394)	4/15/1999 12:50:00 PM
From: Robert Scott	Read Replies (1) \| Respond to of 9523

Hard to believe Viagra went from $236 last quarter to $193 this quarter?? Also, 'The Company's rate of earnings growth in the second quarter compared to the same period in 1998 will be significantly affected by the large initial trade stocking and sales of Viagra, which occurred in the second quarter of 1998 when the product was first launched, and continued strong investment in both R&D and product support,'' Mr. Shedlarz said. ''As a result of these and other factors, Pfizer expects the percentage growth in second quarter 1999 diluted EPS to be in the single-digit range, relative to 1998 diluted EPS excluding the impact of certain significant charges and the divested Medical Technology Group. ''Despite the unique circumstances that will affect second-quarter growth, we believe our full-year 1999 growth prospects remain solid,'' Mr. Shedlarz said. ''For the full year, we are comfortable with the current range of the majority of analysts' estimates for diluted EPS of $2.40 to $2.50, representing 20- to 25-percent growth relative to 1998 diluted EPS excluding the impact of certain significant charges and the divested Medical Technology Group.''